{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lucentis+every+4+weeks",
    "query": {
      "intervention": "Lucentis every 4 weeks"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 33,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lucentis+every+4+weeks&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-13T17:21:53.902Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00509795",
      "title": "Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "ranibizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "aflibercept injection (VEGF Trap-Eye, BAY86-5321)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 1217,
      "start_date": "2007-08",
      "completion_date": "2011-07",
      "has_results": true,
      "last_update_posted_date": "2012-12-28",
      "last_synced_at": "2026-09-13T17:21:53.902Z",
      "location_count": 176,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 144 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00509795"
    },
    {
      "nct_id": "NCT01610557",
      "title": "Ranibizumab and Bevacizumab for Diabetic Macular Edema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Eye Institute (NEI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2012-05",
      "completion_date": "2015-02",
      "has_results": true,
      "last_update_posted_date": "2022-12-09",
      "last_synced_at": "2026-09-13T17:21:53.902Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01610557"
    },
    {
      "nct_id": "NCT00713518",
      "title": "Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study).",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Age Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "0.5 mg ranibizumab",
          "type": "DRUG"
        },
        {
          "name": "3 mg PF-04523655",
          "type": "DRUG"
        },
        {
          "name": "1 mg PF-04523655",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Quark Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 152,
      "start_date": "2009-11",
      "completion_date": "2011-07",
      "has_results": false,
      "last_update_posted_date": "2012-10-12",
      "last_synced_at": "2026-09-13T17:21:53.902Z",
      "location_count": 7,
      "location_summary": "San Francisco, California • Fort Myers, Florida • Winter Haven, Florida + 4 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Winter Haven",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00713518"
    },
    {
      "nct_id": "NCT04503551",
      "title": "A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "PDS Implant Pre-Filled with 100 mg/mL Ranibizumab",
          "type": "DRUG"
        },
        {
          "name": "Intravitreal Ranibizumab 0.5 mg Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 174,
      "start_date": "2020-08-10",
      "completion_date": "2026-02-23",
      "has_results": true,
      "last_update_posted_date": "2026-04-02",
      "last_synced_at": "2026-09-13T17:21:53.902Z",
      "location_count": 64,
      "location_summary": "Mesa, Arizona • Phoenix, Arizona • Bakersfield, California + 59 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04503551"
    },
    {
      "nct_id": "NCT00499590",
      "title": "Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "bevasiranib",
          "type": "DRUG"
        },
        {
          "name": "ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OPKO Health, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 338,
      "start_date": "2007-08",
      "completion_date": "2009-05",
      "has_results": true,
      "last_update_posted_date": "2014-10-06",
      "last_synced_at": "2026-09-13T17:21:53.902Z",
      "location_count": 55,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Fresno, California + 47 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00499590"
    },
    {
      "nct_id": "NCT02127684",
      "title": "Frequent Dosing Regimen of Lucentis for Subjects With Persistent Diabetic Macular Edema Despite Standard antiVEGF Dosing",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Persistent Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Maturi, Raj K., M.D., P.C.",
      "sponsor_class": "INDIV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": null,
      "completion_date": "2015-11",
      "has_results": false,
      "last_update_posted_date": "2014-07-30",
      "last_synced_at": "2026-09-13T17:21:53.902Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02127684"
    },
    {
      "nct_id": "NCT01134055",
      "title": "Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "pazopanib eye drops",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "ranibizumab intravitreal injection",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 510,
      "start_date": "2010-06-01",
      "completion_date": "2012-10-01",
      "has_results": true,
      "last_update_posted_date": "2018-01-08",
      "last_synced_at": "2026-09-13T17:21:53.902Z",
      "location_count": 37,
      "location_summary": "Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 31 more",
      "locations": [
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01134055"
    },
    {
      "nct_id": "NCT01627249",
      "title": "Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "2.0 mg intravitreal aflibercept",
          "type": "DRUG"
        },
        {
          "name": "1.25 mg intravitreal bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "0.3 mg intravitreal ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jaeb Center for Health Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 660,
      "start_date": "2012-08",
      "completion_date": "2019-04-18",
      "has_results": true,
      "last_update_posted_date": "2020-08-10",
      "last_synced_at": "2026-09-13T17:21:53.902Z",
      "location_count": 90,
      "location_summary": "Tucson, Arizona • Beverly Hills, California • Loma Linda, California + 72 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Palm Desert",
          "state": "California"
        },
        {
          "city": "Santa Barbara",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01627249"
    },
    {
      "nct_id": "NCT01934556",
      "title": "A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "Ranibizumab 0.3 mg intravitreal injection",
          "type": "DRUG"
        },
        {
          "name": "Guided Laser Photocoagulation",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Palmetto Retina Center, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 150,
      "start_date": "2013-11",
      "completion_date": "2018-04",
      "has_results": true,
      "last_update_posted_date": "2020-11-17",
      "last_synced_at": "2026-09-13T17:21:53.902Z",
      "location_count": 3,
      "location_summary": "Beverly Hills, California • West Columbia, South Carolina • Houston, Texas",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "West Columbia",
          "state": "South Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01934556"
    },
    {
      "nct_id": "NCT01945866",
      "title": "Phase II Combination Steroid and Anti-VEGF for Persistent DME",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "intravitreal ranibizumab 0.3 mg",
          "type": "DRUG"
        },
        {
          "name": "dexamethasone intravitreal implant",
          "type": "DRUG"
        },
        {
          "name": "Sham injection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Jaeb Center for Health Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 129,
      "start_date": "2014-02",
      "completion_date": "2017-06-05",
      "has_results": true,
      "last_update_posted_date": "2018-09-25",
      "last_synced_at": "2026-09-13T17:21:53.902Z",
      "location_count": 56,
      "location_summary": "Beverly Hills, California • Huntington Beach, California • Loma Linda, California + 47 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        },
        {
          "city": "Redlands",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01945866"
    }
  ]
}